ANXA1 and cancer: In the present study, we found that the novel DNA damage agent lipotecan remarkably releases HMGB1 and ANXA1 at low doses to prompt ICD and increase cancer immunogenicity in vitro and in vivo, suggesting that topoisomerase I (Top I) inhibitors may have the potential to elicit ICD and anticancer immunity.